Schrödinger, Inc.
Financials
Valuation Metrics
Schrödinger, Inc.'s Market Cap is $1.96B. At end of 2025 it was $1.31B. Ranked #1906 of 3,116 in US market (top 61%), #705 of 1,472 on NASDAQ (top 48%), #118 of 203 in Health Care Equipment & Services (top 58%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.96B | US#1,906/3,116 Sec#118/203 |
| Revenue | $259M | US#2,478/3,116 Sec#162/203 |
| Net Income | $-54M | US—/3,116 Sec—/203 |
| Total Assets | $640M | US#2,667/3,116 Sec#150/203 |
| Net Assets | $329M | US#2,467/3,116 Sec#141/203 |
| Employees | 850 | US#2,051/3,116 Sec#143/203 |
| Value | ||
| P/B | 5.95x | US#2,419/3,116 Sec#149/203 |
| P/S | 7.55x | US#2,637/3,116 Sec#175/203 |
| FCF Yield | -1.66% | US—/3,116 Sec—/203 |
| Profitability | ||
| ROE | -16.52% | US#2,446/3,116 Sec#147/203 |
| ROA | -8.48% | US#2,616/3,116 Sec#153/203 |
| Op. Margin | -59.24% | US#2,664/3,116 Sec#183/203 |
| Revenue Growth | 8.88% | US#1,345/3,116 Sec#91/203 |
| Financial Health | ||
| Debt Ratio | 94.67% | US#1,042/3,116 Sec#99/203 |
| Total Debt | $108M | US#2,413/3,116 Sec#137/203 |
| FCF | $-32M | US#2,472/3,116 Sec#172/203 |
| Cash | $288M | US#1,447/3,116 Sec#85/203 |
| Current Ratio | 2.71x | US#878/3,116 Sec#89/203 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,116 Sec—/203 |
| Payout Ratio | 0.00% | US—/3,116 Sec—/203 |
| Performance | ||
| 1Y Return | 24.48% | US#639/3,116 Sec#64/203 |
| 1M Return | -13.59% | US#1,982/3,116 Sec#159/203 |
| From 52W High | -22.47% | US#954/3,116 Sec#88/203 |
| 1Y MDD | -50.18% | US#2,403/3,116 Sec#154/203 |
| Trading | ||
| Volume | 1,251,973 shares | US#1,250/3,116 Sec#69/203 |
| Trading Value | $33M | US#1,450/3,116 Sec#107/203 |
| Per Share | ||
| EPS | $-0.73 | US—/3,116 Sec—/203 |
| BPS | $4.40 | US#2,315/3,116 Sec#146/203 |
Company Info
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.